Angiotensin II Receptor Blockers and Cancer Risk: A Meta-Analysis of Randomized Controlled Trials

Angiotensin II receptor blockers (ARB) are widely used drugs that are proven to reduce cardiovascular disease events; however, several recent meta-analyses yielded conflicting conclusions regarding the relationship between ARB and cancer incidence, especially when ARB are combined with angiotensin-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yun-Tao, Li, Peng-Yang, Zhang, Jian-Qiang, Wang, Lei, Yi, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
3400
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863811/
https://www.ncbi.nlm.nih.gov/pubmed/27149494
http://dx.doi.org/10.1097/MD.0000000000003600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863811/
https://www.ncbi.nlm.nih.gov/pubmed/27149494
http://dx.doi.org/10.1097/MD.0000000000003600

Ejemplares similares